December 10th 2023
Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma
September 30th 2022As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.
Read More
VITALIZE Trial Explores Maveropepimut-S/Pembrolizumab in Relapsed/Refractory DLBCL
September 15th 2022In an interview with Targeted Oncology, Matthew Matasar, MD, discusses background information on the ongoing VITALIZE trial of maveropepimut-S in patients with diffuse large B-cell lymphoma.
Read More
FDA Lifts Partial Clinical Hold on TakeAim Lymphoma Study of Emavusertib/Ibrutinib
August 19th 2022The TakeAim Lymphoma study will continue to evaluate emavusertib with or without ibrutinib in patients with various types of lymphoma after a 4 1/2-month partial clinical hold placed by the FDA.
Read More
FDA Accepts sBLA for Polatuzumab Vedotin Combination in Previously Untreated DLBCL
August 16th 2022By April 2023, the FDA plans have a decision on the approval application for polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone as an option for treatment-naïve diffuse large B-cell lymphoma.
Read More
Zandelisib on Intermittent Dosing Schedule is Safe in R/R B-Cell Malignancies
August 2nd 2022Findings from a phase 1 study concluded zandelisib given to patients with relapsed/refractory B-cell malignancies at 60 mg once daily in an intermittent dosing schedule reflected in a positive safety profile.
Read More
Novel Anti-CD19 CAR T-Cell Therapy Shows Efficacy in Multiple BCL Subtypes
July 30th 2022Manali Kamdar, MD, MBBS, discusses the efficacy and tolerability of a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell lymphoma.
Watch
FDA Grants Fast Track and Rare Pediatric Disease Designations for WU-CART-007 in T-ALL/LBL
July 20th 2022The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Read More